News >

Expert Compares Frontline Immunotherapy Studies in RCC

Jason M. Broderick @jasoncology
Published: Thursday, Nov 07, 2019

Robert J. Motzer, MD

Robert J. Motzer, MD
Three game-changing immunotherapy trials have transformed the treatment paradigm in frontline clear cell renal cell carcinoma (RCC). At the 37th Annual CFS®, Robert J. Motzer, MD, Memorial Sloan Kettering Cancer Center, compared the findings from the three studies.

The 3 phase III randomized trials all had a control arm of single-agent sunitinib (Sutent): the CheckMate 214 trial2 (n = 1096) exploring nivolumab (Opdivo) plus ipilimumab (Yervoy); the KEYNOTE-426 trial3 (n = 861) assessing pembrolizumab (Keytruda) plus the tyrosine kinase inhibitor (TKI) axitinib (Inlyta); and JAVELIN Renal 1014 (n = 886), which explored avelumab (Bavencio) plus axitinib.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication